首页> 外文期刊>Clinical ophthalmology >Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration
【24h】

Foveal atrophy and macular hole formation following intravitreal ranibizumab with/without photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration

机译:玻璃体腔内兰尼单抗联合/不联合光动力疗法治疗年龄相关性黄斑变性继发性脉络膜新生血管后的中央凹萎缩和黄斑孔形成

获取原文
           

摘要

Background: To report the occurrence of foveal atrophy and macular hole formation following intravitreal ranibizumab with or without photodynamic therapy for choroidal neovascularization caused by age-related macular degeneration.Methods: This was a retrospective, interventional case series, in which 78 eyes of 76 patients were treated for wet age-related macular degeneration between February 2007 and August 2007. Of these, three eyes developed foveal atrophy following treatment. Two eyes underwent combination photodynamic therapy and intravitreal ranibizumab, and one eye underwent intravitreal ranibizumab alone. One of the two eyes that underwent combination therapy progressed to develop a macular hole.Results: On the first follow-up visit, all three eyes showed thinning of the fovea on optical coherence tomography. Subsequently, treatment was continued with repeat intravitreal ranibizumab injections. At the last follow-up, although choroidal neovascularization regressed in all eyes, extensive foveal atrophy developed in two eyes with macular hole formation in one eye.Conclusion: The possibility of foveal atrophy and macular hole formation must be borne in mind before initiating ranibizumab in combination with or without photodynamic therapy. However, larger studies with longer follow-up are required to understand such adverse effects better.
机译:背景:报道玻璃体腔内雷珠单抗联合或不联合光动力疗法治疗年龄相关性黄斑变性引起的脉络膜新生血管后黄斑萎缩和黄斑孔形成的方法。这是一项回顾性介入病例系列研究,其中76例患者的78眼在2007年2月至2007年8月之间,对因湿性年龄引起的黄斑变性进行了治疗。其中,三只眼在治疗后出现了中央凹萎缩。两只眼睛接受了光动力疗法和玻璃体内兰尼单抗的联合治疗,一只眼睛单独接受了玻璃体内兰尼单抗的治疗。结果:在首次随访时,三只眼睛在光学相干断层扫描上均显示中央凹变薄。随后,继续进行玻璃体内雷珠单抗注射治疗。在最后一次随访中,尽管所有的眼睛都发生了脉络膜新生血管的形成,但是两只眼睛中都出现了广泛的中央凹萎缩,一只眼睛中形成了黄斑裂孔。结论:在开始使用兰尼单抗之前,必须考虑到中央凹萎缩和黄斑裂孔的可能性。结合或不结合光动力疗法。但是,需要进行更大的随访和更长的研究,才能更好地了解此类不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号